• Adrian Simpson, United States says, "If you are looking for a fair deal on medical supplies, IDM is something I would seriously recommend. Am hooked for life."
  • Craig, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "IDM makes online shopping a pleasure. Shopping is so simple that you just breeze through it."
  • Harry Mason, United States says, "I have to admit am a bit of a lazy bloke when it comes to ordering online .And IDM pampers me to the hit as it's so simple to order."
  • John Hanks, United States says, "I was a sceptic until my first order. After, I received my first package, I turned believer. Now, it’s been 3 years since I have been ordering from IDM."
  • Natalie Wallace, United States says, "I was apprehensive about how my doubts would be addressed but what the heck,I went ahead and placed my order. Customer service was patient and helped me out."
  • Mark Penning, United States says, "Happy I got my package just in time for my vacation. Needless to say, it made my holiday a wonderfully satisfying experience."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    You can find the latest happening of our pharmacy
    Follow us on Twitter

      India, China emerge as world's preferred outsourcing partners in R&D

      Posted AtPharmaBiz

      The rise of India and China as global economies presents immense opportunities for the international pharmaceutical industry. Besieged by ever-increasing cost pressures, shorter product life cycles and numerous regulatory challenges in the west, the industry is increasingly shifting its R&D base to these two developing nations. This is being done primarily to minimise the expenses, time and risk involved in R&D.

      Pharmaceutical companies looking for effective solutions prefer to outsource from low-cost developing countries like India and China rather than persisting with expensive R&D efforts in the west, while taking advantage of the intellectual pool in Asia, according to Sunil Srivastava, president, Richmond Chemical Corporation, US.

      The two countries are keen to increase foreign participation and to figure prominently on the global map and to implement necessary changes to improve clinical research facilities. The regulatory environment in both countries is gradually changing in favour of clinical research.

      The bulk drug business in India is estimated at about USD 1 billion with more than 400 APIs manufactured in India, making the country one of the top five bulk drug manufacturers of the world.

      “With more than 60 US FDA approved units and the US Pharmacopoeia Commission’s laboratory being set up in India, the country is drawing a lot of attention,” Srivastava added.

      Indian companies are now trying to make their mark on a global scale by licensing product abroad, acquisitions of foreign companies, R & D alliances with foreign multinationals and becoming increasingly FDA compliant. The major generic pharmaceutical players together accounted for exports of formulated products and APIs in 2004 of about US $ 1.1 billion. The leading contract manufacturers account for total exports of bulk drug substances of about US $ 80 million in 2004.

      According to IMS Health, the Chinese pharmaceutical market is among the top ten in the world, estimated to be worth USD 10 billion. China has been traditionally a hospital-based pharmaceutical marketplace but the retail sector is growing rapidly and now accounts for about 25 per cent of the total market. The top 10 suppliers to this sector comprise five Chinese companies and five multinationals.

      December 22, 2005


      Share this Article!

    Back to top^